In a paper published in the August 28, 2019 inaugural issue of The Lancet Rheumatology, Professor Huji Xu's team from Beijing Tsinghua Changgung Hospital, Tsinghua University， established clinical equivalence of the domestic biosimilar drugs IBI303 to the control drug adalimumab. This biosimilar drug is expected to benefit patients with ankylosing spondylitis (AS) by lowering the cost of treatment.

　　The Lancet Rheumatology is a new specialty journal published by The Lancet, the world's most renowned medical journal. The research conducted by Professor Huji Xu was presented as the cover issue of the inaugural issue of The Lancet Rheumatology. Professor Huji Xu, Vice President of Beijing Tsinghua Changgung Hospital, was the corresponding author.

　　Huji Xu is Executive Vice Dean of School of Clinical Medicine, Tsinghua University, Chairman of Tsinghua University Academic Committee of Clinical Medicine, and Vice President of Beijing Tsinghua Changgung Hospital. He also serves as Director of Department of Internal Medicine and Department of Rheumatology and Immunology at Changzheng Hospital of Second Military Medical University. Professor Xu is a leading expert both in clinical practice and scientific research, enjoying special allowances from the State Council. He was the Chief Scientist of National Basic Research Programs of China (973 Program and 863 Program). He has led several Major International Cooperation Programs, Key Programs, and General Programs of the National Natural Science Foundation of China, as well as Key Programs in Shanghai. Professor Xu is editorial board member and editor-in-chief of several journals in rheumatology and immunology. He has published 216 papers in high-impact journals such as Nature, Nature Genetics, PNAS, J Exp Med, Ann Rheum Dis, etc, with a cumulative impact factor of over 500. He has served as Vice Chairman of the Rheumatology Branch of the Chinese Medical Association, Vice Chairman of the Rheumatology and Immunology Branch of the Chinese Medical Doctor Association, and Chairman of the Rheumatology Branch of the Shanghai Medical Association.(Reviewer Bin Shu)